论文信息 - Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. - 字舞流文

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.

D. Schadendorf | A. Gesierich | C. Garbe | J. Hou | N. Basset-Seguin | A. Sekulic | D. Murrell | O. Hamid | L. Mortier | M. Migden | C. Lao | H. Yue | F. Quevedo | C. Miller